Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: Experience in sixteen consecutive patients

British Journal of Rheumatology

Volumn 36, Issue 3, 1997, Pages 353-359

  Stevens, R J ^a,b   Andujar, C ^a   Edwards, C J ^a   Ames, P R J ^a   Barwick, A R ^a   Khamashta, M A ^a   Hughes, G R V ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b AMERSHAM HOSPITAL   (United Kingdom)

Author keywords

Adverse effects; Discoid lupus erythematosus; Neuropathy; Subacute cutaneous lupus; Systemic lupus erythematosus; Thalidomide; Treatment

Indexed keywords

THALIDOMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISCOID LUPUS ERYTHEMATOSUS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; HEADACHE; HUMAN; MALE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; SKIN BIOPSY; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; VERTIGO;

ADULT; DRUG TOLERANCE; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; THALIDOMIDE;

EID: 0030843798     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. McBride WG. Thalidomide and congenital abnormalities. Lancet 1962;2:1358.
2. Fullerton PM, Kremer M. Neuropathy after intake of thalidomide (Distival). Br Med J 1961;2:853-8.
3. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965;6:303-6.
4. Gardner-Medwin JM, Powel RJ. Thalidomide - the way forward. Postgrad Med J 1994;70:860-2.
5. Rubio JB, Gonzalez FF. Lupus eritematoso discoide y Talidomida. Dermatol Rev Mex 1975;19:131-9.
6. Knop J, Bonsmann G, Happle R, Ludolph A, Matz DR, Mifsud EJ et al. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. Br J Dermatol 1983;108:461-6.
7. Hasper MF. Chronic cutaneous lupus erythematosus. Thalidomide treatment of eleven patients. Arch Dermatol 1983;119:812-5.
8. Grosshans E, Illy G. Thalidomide therapy for inflammatory dermatoses. Int J Dermatol 1984;23:598-602.
9. Atra E, Sato EI. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol 1993;11:487-93.
10. Naafs B, Bakkers EJM, Flinterman J, Faber WR. Thalidomide treatment of subacute cutaneous lupus erythematosus. Br J Dermatol 1982;107:83-6.
11. Bessis D, Guillot B, Monpoint S, Dandurand M, Guilhou JJ. Thalidomide for systemic lupus erythematosus. Lancet 1992;339:549-50.
12. Tan EM, Cohen AS, Fries JF, Masi AJ et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
13. Powell RJ, Gardner-Medwin JMM. Guideline for the clinical use and dispensing of thalidomide. Postgrad Med J 1994;70:901-4.
14. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumour necrosis factor α production by stimulated human monocytes. J Exp Med 1991;173:699-703.
15. Sampaio EP, Kaplan G, Miranda A, Nery JAC, Miguel CP, Viana SM et al. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993;168:408-14.
16. Gad SM, Shannon EJ, Krotoski WA, Hasting RC. Thalidomide induces imbalances in the T-lymphocyte sub-populations in the circulating blood of healthy males. Leprosy Rev 1985;56:35-9.
17. McHugh SM, Rifkin IR, Deighton J, Wilson AB, Lachman PJ, Lockwood CM et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995;99:160-7.
18. Faure M, Thivolet J, Gaucherand M. Inhibition of polymorphonuclear leukocyte chemotaxis by thalidomide. Arch Dermatol Res 1980;263:275-80.
19. Barnhill RL, Doll NJ, Millikan LE, Hasting RC. Studies on the anti-inflammatory properties of thalidomide; effects on polymorphonuclear leukocyte and monocyte. J Am Acad Dermatol 1984;11:814-9.
20. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91:4082-5.
21. Fullerton PM, O'Sullivan DJ, Thalidomide neuropathy: a clinical, electro-physiological and histological followup study. J Neurol Neurosurg Psychiatry 1968:31: 543-51.
22. Ochonisky S, Verroust J, Bastiju-Garin S, Gheradi R, Revuz J. Thalidomide neuropathy; incidence and electrophysiologic findings in 42 patients. Arch Dermatol 1994;130:66-9.
23. Gardner-Medwin JMM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 1994:53: 828-32.